We’ve all seen the headlines: insulin prices tripling, EpiPen markups, cancer drugs costing more than a house. But the outrage often misses the deeper mechanism. It’s not just that drugs are expensive. It’s that the system rewards certain kinds of drugs—chronic treatments over cures, blockbusters over niche therapies, me-too molecules over true breakthroughs. That’s where the real distortion lies.
The Profit Paradox: Why Cures Are Less Attractive Than Treatments
Here’s a truth most pharma execs won’t say on earnings calls: curing people is bad for business. Treat them for life? Now that’s a revenue stream. A one-time cure for hepatitis C—like Gilead’s Sovaldi—was hailed as a miracle. Yet after its $84,000 price tag sparked public fury, sales collapsed once patients were actually cured. Contrast that with Eli Lilly’s diabetes drug Mounjaro, which pulled in $4.7 billion in 2023 alone—because patients stay on it indefinitely. Chronic disease management is the golden goose.
And that’s exactly where the economic model warps medical progress. Why invest billions in a one-shot gene therapy when you can tweak an existing molecule, rebrand it, and sell it for decades? Take statins. We’ve had them since the 1980s. Yet minor variations keep hitting the market—each with new patents, new pricing power, and marginal clinical benefit. The incentive structure favors iteration over innovation.
But what if we flipped the model? Some experts suggest subscription-style payments—governments pay a flat fee for access to a drug, regardless of volume. This could make cures more appealing. The UK’s NHS has piloted such deals for hepatitis C. Results? Faster eradication, lower overall costs. Yet adoption remains patchy. Why? Because it disrupts the volume-based pricing that fuels shareholder returns.
Patent Games and the Illusion of Innovation
Pharma companies don’t just rely on real breakthroughs—they engineer legal ones. “Evergreening” is the practice of slightly modifying a drug near patent expiry to reset exclusivity. Add a new salt form. Change the release mechanism. File a new patent. And just like that, a drug that should face generics gets another 5–7 years of monopoly pricing. Nexium did this—AstraZeneca’s “purple pill,” spun off from Prilosec. Sales topped $6 billion annually at its peak. Was it better? Marginally. Was it necessary? Debatable.
These maneuvers aren’t illegal. They’re baked into the system. The U.S. grants 20-year patents, but companies often extend protection much longer through secondary claims. A 2019 study found that 78% of new drugs approved between 2015 and 2016 weren’t truly novel—they were variations of existing compounds. You could argue this is smart business. But is it serving public health?
The Neglected Disease Dilemma
Malaria kills over 600,000 people a year—mostly children in sub-Saharan Africa. Yet R&D investment in tropical diseases remains a rounding error in pharma budgets. Why? No one who needs the drugs can pay $10,000 a dose. Antibiotics face a similar fate. Developing a new one might cost $1.5 billion. But because doctors rightly limit their use to avoid resistance, sales volumes stay low. That’s a terrible business model—so companies walk away.
Only 1% of new drugs approved between 2000 and 2017 targeted neglected tropical diseases. That’s not a failure of science. It’s a failure of economics. The thing is, we can fix this—with push and pull incentives. “Push” means funding early research (like the Gates Foundation does). “Pull” means guaranteeing a market (like advanced purchase commitments). But these are exceptions, not the rule.
Drug Pricing: Not Just High—Opaque
You buy a $500 TV. You know the price. You compare models. No mystery. Now try that with Humira. The list price in the U.S. is around $8,000 a month. But insurers don’t pay that. Neither do Medicaid or the VA. They get rebates—sometimes 50% or more. Yet those discounts are secret. Hidden in contracts between manufacturers, pharmacy benefit managers (PBMs), and insurers. So the sticker price balloons, not because of cost, but because of a rebate-driven race to the top.
Here’s how it works: PBMs negotiate rebates as a percentage of list price. Higher list price = bigger rebate = more PBM revenue. Everyone wins—except the patient on a high-deductible plan who pays the full list price until their deductible is met. And surprise—those deductibles keep rising. Since 2010, average employer-based deductibles have tripled, from $1,500 to over $4,500. That’s not a coincidence.
The system incentivizes gamesmanship. Insulin is a case in point. List prices for brands like Humalog and Lantus have more than tripled since 2010. But the actual cost to produce them? Estimates suggest less than $10 per vial. The rest? Middlemen, rebates, administrative bloat. And while Congress talks about capping insulin at $35 a month, the underlying structure remains untouched. That’s like mopping the floor while leaving the faucet running.
The Role of Pharmacy Benefit Managers (PBMs)
Three PBMs—CVS Caremark, UnitedHealth’s OptumRx, and Cigna’s Express Scripts—control over 80% of the U.S. prescription market. They decide which drugs go on formularies, which get preferred status, and how much insurers pay. Yet they operate with little transparency. Their contracts are confidential. Their fees are obscured. And they profit from the spread between what manufacturers rebate and what plans actually pay.
Some states, like Louisiana, have sued PBMs for overcharging public programs. Others have passed laws forcing greater disclosure. But federal reform stalls. Why? Lobbying. The pharmaceutical supply chain spent over $600 million on lobbying in the 2020–2022 cycle. That’s not lobbying against reform—it’s lobbying to preserve the status quo.
Research That Doesn’t Translate: The 90% Failure Rate
For every 10,000 compounds screened, only one makes it to market. The average cost? $2.6 billion. The timeline? 10 to 15 years. Most fail in Phase II trials—too toxic, not effective enough. But here’s the kicker: many failures trace back to poor preclinical models. Mice aren’t humans. Cell cultures don’t replicate organ systems. And yet, that’s where most early research lives.
We pour billions into targets that look promising in petri dishes but collapse in real bodies. Take Alzheimer’s. Over 400 clinical trials have failed since the 1990s. Biogen’s Aduhelm finally got FDA approval in 2021—but with such weak evidence that an advisory committee resigned in protest. The drug costs $28,000 a year. And its real-world benefit? Still debated.
Because the pressure to produce pipeline candidates is so high, companies often rush drugs into trials before the science is solid. The FDA’s accelerated approval pathway—intended for dire unmet needs—gets exploited. Drugs get approved on surrogate endpoints (like tumor shrinkage) without proven survival benefit. Then stay on the market for years while confirmatory trials lag. Sometimes they never confirm. And patients pay the price—literally and physically.
The Replication Crisis in Biomedical Research
A 2012 study by Amgen found that 47 out of 51 landmark cancer studies couldn’t be replicated. That’s not a typo—92% failure rate. Biotech startups have been built on findings that later evaporate. This isn’t fraud. It’s a culture that rewards novelty over rigor. Journals want splashy results. Researchers need publications to get grants. Negative data? Often buried. Methods? Poorly reported.
Fixing this requires cultural change—more funding for replication studies, open data mandates, journals that value robustness. Some progress is happening. But incentives still favor the flashy over the faithful.
Open Science vs. Corporate Secrecy: A Clash of Cultures
Compare the pharma model to something like the Human Genome Project. Publicly funded. Open data. Researchers worldwide collaborated in real time. The genome was mapped in 13 years—years ahead of schedule. Now compare that to how most drug discovery works: walled gardens, trade secrets, NDAs covering every conversation. Progress is siloed. Duplication is rampant.
And yet, when crisis hits, openness wins. During COVID, Moderna shared its mRNA vaccine sequence with the world before human trials began. Researchers in Germany, South Korea, and Brazil used it to accelerate their own work. That’s not typical. It’s exceptional. But it shows what’s possible.
We’re far from it being the norm. Most companies guard data like state secrets. Why? Competitive advantage. But at what cost? Slower progress. Redundant trials. Lost opportunities. The problem is, the current system doesn’t reward sharing. It punishes it.
Frequently Asked Questions
Are Drug Companies Evil?
No. But they’re not charities either. They’re publicly traded entities with fiduciary duties to shareholders. The issue isn’t malice—it’s misaligned incentives. When profit dictates research agendas, public health outcomes become secondary. That doesn’t make them evil. It makes them rational actors in a broken system.
Can Government Fixes Work?
They already do—selectively. The VA negotiates drug prices and pays 40% less than Medicare Part D for the same drugs. The DoD runs a centralized formulary with strict cost controls. But politically, expanding these models nationally faces fierce resistance. Lobbyists call it “government overreach.” I call it learning from what already works.
What Can Consumers Do?
Not much individually. But collectively? Pressure matters. When patients organized against insulin pricing, states like Colorado passed $35 caps. When advocacy groups pushed for faster HIV drug approvals in the 1980s, the FDA listened. Change is slow. But it’s possible. Support transparency, demand value-based pricing, and vote for candidates who challenge the status quo.
The Bottom Line
The biggest problem with the pharmaceutical industry isn’t its profits—it’s that the system rewards the wrong outcomes. Cures over chronic care? Underfunded. Open science? Penalized. Drugs for the poor? Ignored. We’ve built a machine optimized for revenue, not health. And that’s not sustainable.
I find this overrated—the idea that “market forces” alone will fix it. Markets need rules. Without constraints, they exploit inefficiencies. Without transparency, they breed distrust. The solution isn’t to dismantle pharma. It’s to realign it. Reward outcomes, not volume. Fund neglected research. Cap list prices. Force PBM transparency. And stop treating drug development like a quarterly earnings game.
Yes, innovation is expensive. But so is doing nothing. The data is still lacking on long-term societal costs of untreated chronic disease. Experts disagree on how much pricing affects R&D pipelines. Honestly, it is unclear how fast change can come. But one thing isn’t debatable: a system that prioritizes shareholders over survival has lost its moral compass. And that changes everything.